The Federal Government has unveiled a strategic roadmap to integrate gene therapy and frontier medical technologies into the nation’s healthcare system.
This initiative aims to bridge the gap between global scientific innovation and local patient access, positioning Nigeria as a burgeoning hub for advanced medical treatments in Africa.
The move was formalized during a high-level consultative meeting in Abuja involving the Federal Ministry of Health and Social Welfare, the global non-profit Caring Cross, and various research and industry stakeholders.
Closing the Innovation Gap
The Honourable Minister of State for Health and Social Welfare, Dr. Iziaq Adekunle Salako, emphasized that the President Tinubu-led administration is treating health innovation as a matter of national resilience.
By focusing on local production and cutting-edge science, the government intends to drastically reduce the country’s dependence on external supply chains.
“Our goal is clear: to ensure that breakthroughs in science are not distant concepts, but accessible solutions for Nigerians,” Dr. Salako stated. “Nigeria is moving deliberately to close the gap between scientific discovery and patient access, particularly in areas where life-saving treatments remain out of reach for many.”
Pioneering CAR T-Cell Therapy
A primary focus of the new strategy is the introduction of Chimeric Antigen Receptor (CAR) T-cell therapy. This advanced treatment has shown transformative results in managing sickle cell disease and specific blood cancers—conditions that carry a heavy burden in Nigeria. Despite its success globally, CAR-T therapy has remained largely unavailable across the African continent due to cost and technical complexity.
To address this, the government is leveraging the Presidential Initiative on Vaccine and Biologicals Production (PVAC). This framework is designed to overhaul pharmaceutical research, expand the production of biologicals, and create a coordinated ecosystem where high-tech innovations can be manufactured and administered locally.
Strategic Global Partnerships
The Permanent Secretary of the Ministry, Daju Kachollom S. mni, represented by the Director of Health Planning, Research & Statistics, characterized the initiative as a “convergence of science, policy, and opportunity.” She noted that regenerative medicine offers Nigeria a unique chance to leapfrog traditional healthcare limitations.
Dr. Boro Dropulic, CEO of Caring Cross, highlighted his organization’s commitment to making cellular therapies affordable and scalable for low- and middle-income nations. He cited the rising prevalence of genetic and blood-related diseases among Nigerian children as a primary catalyst for accelerating access to these next-generation cures.
A Shift Toward Local Leadership
The Director-General of the National Institute of Pharmaceutical Research and Development (NIPRD), Dr. Obi Adigwe, confirmed that Nigeria is already securing international research funding and upgrading infrastructure for the production of Active Pharmaceutical Ingredients (APIs).
By fostering a multi-sector approach, the Federal Government aims to transition Nigeria from a mere consumer of foreign medicine to an active participant in the development and adaptation of advanced therapies, ensuring long-term medicine security for its over 200 million citizens.
Share this
